Penn Medicine Blocks Parkinson's Protein Spread in 1,675-Brain Study as GPNMB Emerges Target
Updated
Updated · Penn Medicine · May 12
Penn Medicine Blocks Parkinson's Protein Spread in 1,675-Brain Study as GPNMB Emerges Target
4 articles · Updated · Penn Medicine · May 12
Monoclonal antibodies against GPNMB stopped alpha-synuclein pathology from spreading between cultured neurons in Penn Medicine preclinical experiments, pointing to a potential disease-modifying approach for Parkinson’s.
Microglia emerged as a major source of GPNMB: when nearby neurons are injured, they release more of the immune protein, which researchers say helps drive a self-reinforcing cycle of neuronal damage and protein spread.
Analysis of 1,675 brains in the Penn Brain Bank linked genetic variants tied to higher GPNMB production with more extensive alpha-synuclein pathology, strengthening the case that the protein is central to Parkinson’s progression.
Parkinson’s affects more than 1 million Americans and brings about 90,000 new U.S. diagnoses each year, yet current treatments mainly ease symptoms rather than slow the disease itself.
With new drugs already lowering GPNMB, is this breakthrough a new path or one piece of a much larger puzzle?
After amyloid antibody failures in Alzheimer's, can targeting a single protein truly halt Parkinson's progression?
GPNMB Identified as Key Driver of Parkinson’s Progression: New Hope for Disease-Modifying Therapies
Overview
Penn Medicine researchers have identified GPNMB, a protein produced by the brain’s immune cells called microglia, as a key player in Parkinson’s disease progression. GPNMB acts as a conduit that enables the transfer of toxic alpha-synuclein aggregates between neurons. This intercellular transfer is crucial because it drives the spread of Parkinson’s pathology throughout the brain, leading to worsening symptoms. By understanding how GPNMB facilitates this harmful process, scientists have uncovered a promising target for therapies that could slow or stop the progression of Parkinson’s disease, moving beyond just managing symptoms.